All In Biotech

Drug Trial Radar · NCT05996380

A Phase 1 Trial to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SHR-3167 Single Injection in Healthy Subjects and Patients With Type 2 Diabetes

A Phase 1 Trial to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SHR-3167 Single Injection in Healthy Subjects and Patients With Type 2 Diabetes

Last checked: Nov 19, 2026Latest source record: Oct 11, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

52

Planned (sponsor's estimate)

Start

Jun 9, 2023

Primary completion

Jan 25, 2024

Study completion Apr 28, 2024

Sponsor

Sponsor type
Industry
First posted
Aug 18, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, placebo-controlled, single-dose escalation trial was designed. There are 6 dose groups and 1 optional dose group: 0.5 mg, 2 mg, 8 mg, 25mg, 50 mg, 100 mg and 150 mg (optional). Eight healthy adult subjects or T2DM patients in each dose group (except for 0.5 mg dose group, only 4 subjects will be enrolled) are randomly assigned to subcutaneously injection of SHR-3167 or placebo according to 3:1 ratio.

Conditions

  • T2DM

Interventions

  • SHR-3167Drug

    SHR-3167, Single administration

  • SHR-3167 PlaceboDrug

    SHR-3167 Placebo Single administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety endpoints: Number of Adverse EventsTime frame: Start of Treatment to end of study (approximately 92 days)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Jiangsu Province Hospital

    Nanjing, Jiangsu, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.